HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
Stopped Decision by the company to terminate the H-300-001 study early for non-safety related reasons.
Conditions
- Prostate Cancer Metastatic
Interventions
- BIOLOGICAL: HB-302/HB-301 Alternating 2-Vector Therapy
Sponsor
Hookipa Biotech GmbH